Skip to Content



(MAN ga nees)

Index Terms

  • Manganese Chloride
  • Manganese Sulfate

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral, as chelated:

MN-50: Elemental manganese 16.67 mg

Solution, Intravenous, as chloride:

Generic: Elemental manganese 0.1 mg/mL (10 mL)

Solution, Intravenous, as sulfate [preservative free]:

Generic: Elemental manganese 0.1 mg/mL (10 mL [DSC])

Tablet, Oral, as aspartate:

Generic: 93 mg [elemental manganese 25 mg]

Tablet, Oral, as chelated:

Mangimin: Elemental manganese 10 mg [corn free, rye free, wheat free]

Generic: Elemental manganese 15 mg, Elemental manganese 50 mg

Tablet, Oral, as gluconate:

Generic: 50 mg [elemental manganese 5.7 mg]

Brand Names: U.S.

  • Mangimin [OTC]
  • MN-50 [OTC]

Pharmacologic Category

  • Dietary Supplement
  • Trace Element, Parenteral


Cofactor in many enzyme systems, stimulates synthesis of cholesterol and fatty acids in liver, and influences mucopolysaccharide synthesis




Concentrated in mitochondria of pituitary gland, pancreas, liver, kidney, and bone


Bile (primarily); urine (negligible)

Use: Labeled Indications

Trace element added to total parenteral nutrition (TPN) solution to prevent manganese deficiency; orally as a dietary supplement


Direct IM or IV injection

Dosing: Adult

Adequate intake: Oral:

Males: 2.3 mg/day; Females: 1.8 mg/day

Pregnancy: 2 mg/day

Lactation: 2.6 mg/day

Deficiency prevention: IV: 150-800 mcg/day usually administered in TPN solutions

Dosing: Geriatric

Refer to adult dosing.

Dosing: Pediatric

Adequate intake: Oral:

0-6 months: 0.003 mg/day

7-12 months: 0.6 mg/day

1-3 years: 1.2 mg/day

4-8 years: 1.5 mg/day

9-13 years: Males: 1.9 mg/day; Females: 1.6 mg/day

14-18 years: Males: 2.2 mg/day; Females: 1.6 mg/day

Deficiency prevention: IV: 2-10 mcg/kg/day usually administered in TPN solutions

Note: Use caution in premature neonates; manganese chloride solution for injection contains aluminum.

Dosing: Renal Impairment

Use caution; manganese chloride solution for injection contains aluminum.

Dosing: Hepatic Impairment

Use caution; dose may need to be decreased or withheld.


Capsule, tablet: May be administered with a meal.

Solution for injection: Do not administer IM or by direct IV injection; acidic pH of the solution may cause tissue irritations and it is hypotonic; administer after dilution in volume of fluid ≥100 mL


Capsule/tablet (dietary supplement): Store in a cool, dry place.

Solution for injection: Store at controlled room temperature of 20°C to 25°C (68°F to 77°F). Compatible with electrolytes usually present in amino acid/dextrose solution used for TPN solutions; after admixture, discard unused portion immediately.

Drug Interactions

There are no known significant interactions.


Disease-related concerns:

• Biliary tract impairment: Use with caution in patients with biliary tract impairment; dose may need to be decreased or withheld.

• Hepatic impairment: Use with caution in patients with hepatic impairment; dose may need to be decreased or withheld.

Dosage form specific issues:

• Aluminum: The parenteral product may contain aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of >4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses (Federal Register, 2002). See manufacturer’s labeling.

Other warnings/precautions:

• Appropriate use: Due to its highly acidic pH (pH 2.0), direct IV or IM injection is contraindicated; may result in severe tissue damage.

Monitoring Parameters

Periodic manganese plasma level

Pregnancy Risk Factor


Pregnancy Considerations

Animal reproduction studies have not been conducted. Manganese crosses the placenta and can be detected in placental tissue and cord blood (Osada, 2002).

Patient Education

• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)

• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.

Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating, and advising patients.